BR112017016330A2 - anticorpos anti-transtiretina - Google Patents

anticorpos anti-transtiretina

Info

Publication number
BR112017016330A2
BR112017016330A2 BR112017016330A BR112017016330A BR112017016330A2 BR 112017016330 A2 BR112017016330 A2 BR 112017016330A2 BR 112017016330 A BR112017016330 A BR 112017016330A BR 112017016330 A BR112017016330 A BR 112017016330A BR 112017016330 A2 BR112017016330 A2 BR 112017016330A2
Authority
BR
Brazil
Prior art keywords
ttr
antibodies
transthyretin
accumulation
amyloidosis
Prior art date
Application number
BR112017016330A
Other languages
English (en)
Inventor
Chakrabartty Avijit
N Higaki Jeffrey
S Nijjar Tarlochan
Liu Yue
Original Assignee
Prothena Biosciences Ltd
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Univ Health Network filed Critical Prothena Biosciences Ltd
Publication of BR112017016330A2 publication Critical patent/BR112017016330A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção provê anticorpos que se ligam especificamente à transtiretina (ttr). os anticorpos podem ser utilizados para tratar ou efetuar profilaxia de doenças ou distúrbios associados ao acúmulo de ttr ou acumulo de depósitos de ttr (por exemplo, amiloidose ttr). os anticorpos também podem ser usados para diagnosticar a amiloidose ttr e inibir ou reduzir a agregação de ttr, entre outras aplicações.
BR112017016330A 2015-01-28 2016-01-28 anticorpos anti-transtiretina BR112017016330A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562109002P 2015-01-28 2015-01-28
US201562266556P 2015-12-11 2015-12-11
PCT/IB2016/050415 WO2016120810A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (1)

Publication Number Publication Date
BR112017016330A2 true BR112017016330A2 (pt) 2018-04-03

Family

ID=55299694

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016330A BR112017016330A2 (pt) 2015-01-28 2016-01-28 anticorpos anti-transtiretina

Country Status (32)

Country Link
US (1) US20160251418A1 (pt)
EP (2) EP4134379A1 (pt)
JP (2) JP6748086B2 (pt)
KR (2) KR102598180B1 (pt)
CN (1) CN107406499B (pt)
AU (1) AU2016210888C1 (pt)
BR (1) BR112017016330A2 (pt)
CA (1) CA2974912A1 (pt)
CL (2) CL2017001924A1 (pt)
CO (1) CO2017008476A2 (pt)
CU (1) CU24480B1 (pt)
DK (1) DK3250592T3 (pt)
EA (1) EA036080B1 (pt)
ES (1) ES2934656T3 (pt)
FI (1) FI3250592T3 (pt)
HR (1) HRP20221538T1 (pt)
HU (1) HUE060878T2 (pt)
IL (1) IL253633B (pt)
LT (1) LT3250592T (pt)
MX (1) MX2017009806A (pt)
PE (1) PE20180217A1 (pt)
PH (1) PH12017501318B1 (pt)
PL (1) PL3250592T3 (pt)
PT (1) PT3250592T (pt)
RS (1) RS63906B1 (pt)
SA (1) SA517382002B1 (pt)
SG (2) SG11201706124VA (pt)
SI (1) SI3250592T1 (pt)
TW (2) TWI718122B (pt)
UA (1) UA122142C2 (pt)
WO (1) WO2016120810A1 (pt)
ZA (1) ZA201705663B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
CU20200022A7 (es) * 2017-10-06 2021-01-12 Prothena Biosciences Ltd Métodos para detectar transtiretina
EP3691447A4 (en) 2017-10-06 2021-08-11 Prothena Biosciences Limited ANTI-TRANSTHYRETINE ANTIBODIES
AU2018375356A1 (en) 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
EP3876713B1 (en) 2018-11-09 2024-10-02 Neurimmune AG Patient-derived amyloid xenograft rodent model
EP4121766A1 (en) 2020-03-18 2023-01-25 AL-S Pharma AG Misfolded sod1 assay
CN115551886A (zh) 2020-05-12 2022-12-30 生物控股有限公司 用于ttr淀粉样变性的联合疗法
WO2021231982A1 (en) * 2020-05-14 2021-11-18 City Of Hope Smc1a antibodies and uses thereof
JP2023548005A (ja) * 2020-10-28 2023-11-15 ノヴォ ノルディスク アー／エス 抗トランスサイレチン抗体およびその使用方法
CN113845593B (zh) * 2021-10-27 2023-03-10 福州迈新生物技术开发有限公司 抗α-SMA蛋白单克隆抗体、细胞系及其应用
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
WO2024086684A2 (en) * 2022-10-19 2024-04-25 Ibio, Inc. Chemokine receptor 8 (ccr8) antibodies
WO2024105062A1 (en) 2022-11-15 2024-05-23 Neurimmune Ag Methods for treating or preventing transthyretin-mediated amyloidosis

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
KR100444778B1 (ko) 1999-02-05 2004-08-18 삼성전자주식회사 영상 텍스쳐 추출 방법 및 그 장치
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
MXPA05005481A (es) 2002-11-29 2005-07-25 Boehringer Ingelheim Pharma Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
KR101235658B1 (ko) 2004-11-10 2013-02-21 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Ｃｈｏ 세포에 대한 세포 뱅킹 전략을 최적화하기 위한 유동 세포측정 분석의 용도
EP2021340B1 (en) 2006-04-21 2014-07-23 The Government Of The United States, As Represented by The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
TWI419902B (zh) 2007-03-02 2013-12-21 百靈佳殷格翰製藥公司 蛋白質產製之改良
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
FI20115165A0 (fi) * 2011-02-21 2011-02-21 Polysackaridforskning I Uppsala Ab Terapeuttisia ja diagnostisia menetelmiä
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
WO2014124334A2 (en) * 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
EP3022225B1 (en) 2013-07-19 2021-09-29 Board Of Regents Of the University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
CU20200022A7 (es) 2017-10-06 2021-01-12 Prothena Biosciences Ltd Métodos para detectar transtiretina

Also Published As

Publication number Publication date
EP3250592A1 (en) 2017-12-06
TW201632554A (zh) 2016-09-16
AU2016210888B2 (en) 2021-11-04
CN107406499A (zh) 2017-11-28
IL253633B (en) 2021-06-30
EP3250592B1 (en) 2022-10-05
SG10202101763VA (en) 2021-04-29
CL2017001924A1 (es) 2018-04-27
UA122142C2 (uk) 2020-09-25
MX2017009806A (es) 2018-08-15
TWI718122B (zh) 2021-02-11
SA517382002B1 (ar) 2021-11-25
CU24480B1 (es) 2020-03-04
CO2017008476A2 (es) 2018-01-16
AU2016210888C1 (en) 2022-06-02
DK3250592T3 (en) 2023-01-09
SG11201706124VA (en) 2017-08-30
AU2016210888A1 (en) 2017-08-10
CU20170097A7 (es) 2018-03-13
PE20180217A1 (es) 2018-01-31
LT3250592T (lt) 2023-02-10
JP6748086B2 (ja) 2020-09-02
EA201791712A1 (ru) 2017-12-29
RS63906B1 (sr) 2023-02-28
CN107406499B (zh) 2021-10-22
JP7028923B2 (ja) 2022-03-02
CL2022003027A1 (es) 2023-06-09
KR20230156164A (ko) 2023-11-13
PL3250592T3 (pl) 2023-06-19
KR102598180B1 (ko) 2023-11-03
ZA201705663B (en) 2018-08-29
TW202124436A (zh) 2021-07-01
JP2018506277A (ja) 2018-03-08
EP4134379A1 (en) 2023-02-15
PT3250592T (pt) 2022-12-28
EA036080B1 (ru) 2020-09-23
FI3250592T3 (fi) 2023-01-13
WO2016120810A1 (en) 2016-08-04
CA2974912A1 (en) 2016-08-04
JP2020185009A (ja) 2020-11-19
HUE060878T2 (hu) 2023-04-28
ES2934656T3 (es) 2023-02-23
IL253633A0 (en) 2017-09-28
PH12017501318A1 (en) 2018-02-05
US20160251418A1 (en) 2016-09-01
KR20170106469A (ko) 2017-09-20
HRP20221538T1 (hr) 2023-03-03
KR102677203B1 (ko) 2024-06-20
TWI786505B (zh) 2022-12-11
PH12017501318B1 (en) 2018-02-05
SI3250592T1 (sl) 2023-03-31

Similar Documents

Publication Publication Date Title
BR112017016330A2 (pt) anticorpos anti-transtiretina
BR112017016324A2 (pt) anticorpos anti-transtiretina
BR112017016345A2 (pt) anticorpos anti-transtiretina
BR112016016436A2 (pt) moléculas de anticorpo para tim-3 e usos das mesmas
BR112019003976A2 (pt) anticorpos anti-tim-3 e seu uso
CU20200021A7 (es) Anticuerpos anti-transtiretina
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
WO2018007924A3 (en) Anti-transthyretin antibodies
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
CU20170052A7 (es) Moléculas de anticuerpo que se unen a pd-l1
WO2018007923A3 (en) Anti-transthyretin antibodies
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
WO2018007922A3 (en) Anti-transthyretin antibodies
BR112018072389A2 (pt) anticorpos que reconhecem tau
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
BR112018072394A2 (pt) anticorpos que reconhecem a tau
AR113345A1 (es) Anticuerpos anti-transtiretina
MY193688A (en) Anti-transthyretin antibodies
EA202090898A1 (ru) Антитранстиретиновые антитела
EA202090891A1 (ru) Молекулы антител против cd138 и их применение
BR112017007112A2 (pt) compostos de 1,2-benzotiazol para o tratamento de distúrbios renais
AR103548A1 (es) Anticuerpos anti-transtiretina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2016, OBSERVADAS AS CONDICOES LEGAIS